ISI Web of Knowledge Take the next step  
Web of Science®
 
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
RENAL-DISEASE AND PATIENT SURVIVAL IN LIGHT-CHAIN DEPOSITION DISEASE
Author(s): POZZI C, FOGAZZI GB, BANFI G, STROM EH, PONTICELLI C, LOCATELLI E
Source: CLINICAL NEPHROLOGY    Volume: 43    Issue: 5    Pages: 281-287    Published: MAY 1995  
Times Cited: 28     References: 34     
Abstract: We evaluated retrospectively the presenting clinical features, response to treatment and clinical course of 19 patients with LCDD, 11 of whom had multiple myeloma. At presentation, renal insufficiency was present in 18 patients and proteinuria in 16. Renal biopsy revealed typical LCDD in 16 patients, while in the remaining three LCDD was associated with other abnormal tissue deposits. Extrarenal signs were observed in 12 patients (63%), with the liver, heart and peripheral nerves being the most frequently involved organs. After diagnosis, 18 patients underwent therapy: 2 received steroids alone and 16 were treated with steroids and cytotoxic drugs; 7 patients also underwent plasma exchange. At the end of the first month of treatment renal function improved in 5 patients, worsened in 5 and remained unchanged in 8. All but 3 of the patients continued treatment beyond the first month: 7 patients developed end-stage renal disease, 5 an improvement and 4 a worsening in renal function. No effect on proteinuria was observed. Extrarenal symptoms developed in 4 previously unaffected patients and in 3 others they extended to more organs. Sixteen patients died: 12 during the first year of the follow-up, and 4 at 21st, 34th, 37th and 82nd month of observation. Five patients died from neoplastic cachexia, 4 from hypokinetic cardiopathy, 3 from hemorrhagic complications, 2 from pneumonia and one from unknown cause. Mean patient survival after presentation was 18.1 +/- 20.7 months. In our patients clinical outcome was generally very poor, and it was probably influenced by the high prevalence of multiple myeloma, the multiorgan involvement of extrarenal disease and the presence of different types of deposits in some patients. In conclusion, LCDD in patients with renal disease is very serious, extrarenal involvement is frequent and therapy has beneficial effects only in a minority of patients.
Document Type: Article
Language: English
Reprint Address: POZZI, C (reprint author), OSPED LECCO, DIV NEFROL & DIALISI, VIA GHISLAMZONI 22, I-22053 LECCO, ITALY
Addresses:
1. OSPED MAGGIORE, IRCCS, DIV NEFROL & DIALISI, MILAN, ITALY
2. UNIV BASEL, INST PATHOL, BASEL, SWITZERLAND
Publisher: DUSTRI-VERLAG DR KARL FEISTLE, BAHNHOFSTRABE 9 POSTFACH 49, W-8024 MUNCHEN-DEISENHOFEN, GERMANY
Subject Category: Urology & Nephrology
IDS Number: QZ805
ISSN: 0301-0430
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
  
Thomson Reuters Logo